Differential effects of sorafenib on liver versus tumor fibrosis mediated by SDF1α/CXCR4 axis and Gr-1+ myeloid cell infiltration in mice

Sorafenib—a broad kinase inhibitor—is a standard therapy for advanced hepatocellular carcinoma (HCC), and has been shown to exert anti-fibrotic effects in liver cirrhosis, a precursor of HCC. However, the effects of sorafenib on tumor desmoplasia—and its consequences on treatment resistance — remain...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Chen, Yunching, Huang, Yuhui, Reiberger, Thomas, Duyverman, Annique M., Huang, Peigen, Samuel, Rekha, Hiddingh, Lotte, Roberge, Sylvie, Koppel, Christina, Lauwers, Gregory Y., Zhu, Andrew X., Jain, Rakesh K., Duda, Dan G.
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3966948/
https://ncbi.nlm.nih.gov/pubmed/24242874
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/hep.26790
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky